同源重组基因克隆性突变预测卵巢癌铂类化疗预后良好
研究对385例接受铂类化疗的卵巢癌进行体细胞有害突变克隆性分析,发现DDR通路突变存在广泛克隆异质性,DDR克隆突变患者呈超突变表型。HRR克隆突变者OS和PFS显著优于HRR野生型,HRR亚克隆突变与预后无关;独立93例队列验证了该发现。
要点
- HRR克隆突变与卵巢癌铂类化疗后更好OS和PFS相关
- HRR亚克隆突变与预后无关
- HRR克隆突变者化疗敏感率和PFI更高
核心结论
- HRR克隆突变而非亚克隆突变与卵巢癌铂类化疗后生存改善、化疗反应和基因组不稳定性相关。
研究设计与样本
- 对385例接受铂类化疗的卵巢癌进行体细胞有害突变克隆性推断的整合分析,并用93例独立队列验证。
主要发现
- DDR通路体细胞有害突变呈现广泛克隆异质性,DDR克隆突变患者呈超突变表型。
- HRR克隆突变者OS显著优于HRR野生型(HR=0.19,95%CI 0.06-0.59,P=0.0044)。
- HRR克隆突变者PFS显著优于HRR野生型(HR=0.20,95%CI 0.08-0.49,P=0.0005)。
- HRR亚克隆突变与预后无关。
- HRR克隆突变者化疗敏感率显著更高(P=0.0027),PFI更长(HR=0.20,95%CI 0.08-0.49,P=0.0005)。
临床怎么用
- 卵巢癌铂类化疗前可评估HRR突变克隆性,克隆性突变提示化疗敏感和预后较好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Platinum-based chemotherapy remains the first-line treatment for ovarian carcinoma by inducing DNA damage. The therapeutic impact of clonal and subclonal somatic mutations in DNA damage repair (DDR) pathways remains unexplored. METHODS: We performed an integrated analysis to infer the clonality of somatic deleterious mutations in 385 ovarian carcinomas treated with platinum-based chemotherapy. The Kaplan-Meier method was performed for visualization and the differences between survival curves were calculated by log-rank test. Proportional hazards models were used to estimate relative hazards for platinum-free interval (PFI), progression-free survival (PFS) and overall survival (OS). RESULTS: We found that somatic deleterious mutations in DDR pathways exhibited widespread clonal heterogeneity, and that patients with DDR clonal mutations exhibited a "hypermutator phenotype". Clonal somatic mutations in homologous recombination repair (HRR) pathway were significantly associated with better OS (HR = 0.19 (95% CI, 0.06-0.59), P = 0.0044) and PFS (HR = 0.20 (95% CI, 0.08-0.49), P = 0.0005) than HRR wild-type, while HRR subclonal mutations were not associated with prognosis. Moreover, HRR clonal mutations were associated with significantly higher chemotherapy sensitive rate (P = 0.0027) and longer PFI (HR = 0.20 (95% CI, 0.08-0.49), P = 0.0005) than HRR wild-type, while HRR subclonal mutations were not. We validated our findings using an independent cohort of 93 ovarian cancer patients that received platinum-based chemotherapy. CONCLUSIONS: HRR clonal mutations, but not subclonal mutations, were associated with improved survival, chemotherapy response, and genome instability compared with HRR wild-type.
引用
- Luo S, Zhang Y, Yang Y, et al. Clonal tumor mutations in homologous recombination genes predict favorable clinical outcome in ovarian cancer treated with platinum-based chemotherapy. Gynecol Oncol. 2020. PMID: 32402633. doi:10.1016/j.ygyno.2020.04.695
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。